Kurs
-0,28%
Kurs
-0,28%
Open
18,52
High
18,52
Low
17,82
Close
18,09
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
7,45 MNOK
Likviditet
7,45 MNOK
Rel. mcap
0,73%
Antal aktier
412 261
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2027-02-24 | 07:00 | Bokslutskommuniké 2026 |
| 2026-11-25 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-08-26 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-27 | - | Kvartalsrapport 2026-Q1 |
| 2026-05-15 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2026-05-13 | - | Årsstämma |
| 2026-02-25 | - | Bokslutskommuniké 2025 |
| 2026-01-21 | - | Extra Bolagsstämma 2026 |
| 2025-11-24 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-27 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-27 | - | X-dag ordinarie utdelning NYKD 1.00 NOK |
| 2025-05-26 | - | Årsstämma |
| 2025-04-23 | - | Extra Bolagsstämma 2025 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2023-11-07 08:30:00
Oslo, Norway, November 7, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig, will present and host 1x1 meetings at the 2023
Jefferies Healthcare Conference in London on Thursday, November 16, 2023, at
8:00 a.m. GMT / 9:00 a.m. CET.
The presentation slides will be available in the Investors section of the
Company's website at
https://nykode.com/investors/financial-reports-and-presentations/.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells (APC), which have been
shown to induce broad, strong, and long-lasting antigen specific immune
responses which correlates with clinical responses in cancer.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer